Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1180-1184

  MacLeod, David L ^a,c   Nelson, Laura E ^a   Shawar, Ribhi M ^a   Lin, Betty B ^a   Lockwood, Luann G ^a   Dirks, Joy E ^a   Miller, George H ^b   Burns, Jane L ^a   Garber, Richard L ^a  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b Microcide Pharmaceuticals   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; PLACEBO; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; GENOTYPE; IMMUNE SYSTEM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERMEABILITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 0034031728     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315312     Document Type: Article

References (15)

1. 1. Hurley JC, Miller GH, Smith AL. Mechanisms of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Diagn Microbiol Infect Dis 1995; 22:331-6.
2. 2. Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-7.
3. 3. Ramsey BW, Pepe MS, Quan JM, et al. Chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30.
4. 4. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-6.
5. 5. Burns JL, Stapp JR, Yim DL, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158-63.
6. 6. Bukanov N, Ravi VN, Miller D, Srivastava K, Berg DE. Pseudomonas aeruginosa corneai ulcer isolates distinguished using the arbitrarily primed PCR DNA fingerprinting method. Curr Eye Res 1994; 13:783-90.
7. 7. Shaw KJ, Hare RS, Sabatelli FJ, et al. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob Agents Chemother 1991; 35:2253-61.
8. 8. Levesque C, Piché L, Larose C, Roy PH. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob Agents Chemother 1995; 39:185-91.
9. 9. National Committee for Clinical Laboratory Standards. Performance standards tor antimicrobial susceptibility testing. 8th informational supplement. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999:M100-S9.
10. 10. Casin I, Bordon F, Bertin P, et al. Aminoglycoside 6′-N-acetyltransferase variants of the Ib type with altered substrate profile in clinical isolates of Enterobacter cloacae and Citrobacter freundii. Antimicrob Agents Chemother 1998; 42:209-15.
11. 11. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57:138-63.
12. 12. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The most frequently occurring aminoglycoside resistance mechanisms - combined results of surveys in eight regions of the world. J Chemother 1995; 7:17-30.
13. 13. Renders NH, Sijmons MA, van Belkum A, Overbeek SE, Mouton JW, Verbrugh HA. Exchange of Pseudomonas aeruginosa isolates among cystic fibrosis siblings. Res Microbiol 1997; 148:447-54.
14. 14. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-74.
15. 15. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980; 28:546-56.